A 28-year-old woman with moderate persistent asthma is started on inhaled fluticasone propionate 250 µg twice daily via metered-dose inhaler (MDI). After 6 weeks of therapy, she reports good symptom control with no exacerbations. Regarding the pharmacology and clinical use of ICS in this patient, all of the following are true EXCEPT:

Question

Accepted Answer

C. ICS must be administered immediately before exercise in asthma patients to provide acute bronchodilation and prevent exercise-induced bronchoconstriction. ## Clinical Use and Pharmacology of Inhaled Corticosteroids

### Correct Statements (Options 0, 2, 3)

**Key Point:** Regular ICS therapy is the cornerstone of asthma maintenance treatment. It reduces exacerbation frequency by 50–60% and decreases the need for rescue beta-2 agonists through suppression of airway inflammation, eosinophilia, and mucus production [cite:Harrison 21e Ch 242].

**Clinical Pearl:** Systemic side effects of ICS include:
  - Adrenal suppression (HPA axis suppression) — dose-dependent, more common with high-dose ICS
  - Growth retardation in children — typically 1–2 cm reduction in final height with high-dose therapy
  - Osteoporosis with prolonged use
  - Increased infection risk (relative)

Use of spacer devices significantly reduces systemic absorption and side effects.

**High-Yield:** ICS + LABA combination therapy is superior to either agent alone in moderate-to-severe asthma. Guidelines recommend ICS/LABA as the preferred step-3 therapy (GINA 2023). Examples: fluticasone/salmeterol, budesonide/formoterol.

### Why Option 1 Is Incorrect

**Warning:** ICS are **NOT** acute bronchodilators and do **NOT** provide rapid relief of bronchoconstriction. They must be used regularly (maintenance therapy) to prevent symptoms, not acutely before exercise.

**Mnemonic:** **LABA-SABA Rule** — Long-Acting Beta-2 Agonists (LABA) and Short-Acting Beta-2 Agonists (SABA) provide acute relief; ICS provide chronic control.

**Clinical Pearl:** For exercise-induced bronchoconstriction (EIB), the correct approach is:
  1. Regular ICS maintenance therapy to reduce baseline hyperresponsiveness
  2. SABA (albuterol) 15 minutes **before** exercise for acute prevention
  3. ICS does NOT replace SABA for acute pre-exercise prophylaxis

### Mechanism Timeline Table

| Agent Class | Onset | Duration | Role in EIB |
| --- | --- | --- | --- |
| SABA (albuterol) | 5–15 min | 4–6 hours | Acute pre-exercise prophylaxis |
| LABA (salmeterol) | 10–20 min | 12 hours | Maintenance + some EIB protection |
| ICS (fluticasone) | 2–4 weeks | Chronic | Reduces baseline hyperresponsiveness; NOT acute |
| Leukotriene antagonist | 2–4 weeks | Chronic | Maintenance; some EIB benefit |

**High-Yield:** The 2–4 week lag to maximal ICS effect is why patients must be counseled that ICS is NOT a rescue medication.

Answer

A. Adrenal suppression and growth retardation are potential systemic side effects of ICS, particularly in children receiving high-dose therapy or using non-spacer delivery

Answer

B. ICS efficacy is enhanced when combined with long-acting beta-2 agonists (LABA), and this combination is preferred over ICS monotherapy in moderate-to-severe asthma

Answer

D. Regular ICS therapy reduces the need for short-acting beta-2 agonists and decreases asthma exacerbation frequency by suppressing airway eosinophilia and mucus hypersecretion

Explanation

Practice similar questions